Lantheus (LNTH) vs QuidelOrtho (QDEL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Lantheus (LNTH) has outperformed QuidelOrtho (QDEL) over the past year, gaining 82.9% versus a loss of 65.8%. Over five years, LNTH leads with a +266.1% price change compared with -94.3% for QDEL. Lantheus is the larger company by market cap ($6.68 billion vs $570.9 million), about 11.7 times the size.
On valuation, QuidelOrtho trades at a lower forward P/E (6.3x vs 15.3x for Lantheus). Lantheus converts more of its revenue into profit, with a net margin of 15.2% versus -41.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LNTH | QDEL |
|---|---|---|
| Share price | $102.10 | $8.32 |
| Market cap | $6.68B | $570.86M |
| 1-day change | 0.00% | -6.73% |
| YTD return | +53.42% | -70.87% |
| 1-year return | +82.91% | -65.83% |
| 5-year return | +266.08% | -94.25% |
| P/E ratio (TTM) | 25.40 | — |
| Forward P/E | 15.34 | 6.32 |
| EPS (TTM) | $4.02 | $-5.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.54B | $2.73B |
| Revenue growth (YoY) | +0.50% | -1.89% |
| Net income (latest FY) | $233.56M | $-1.13B |
| Gross margin | 61.10% | 46.67% |
| Operating margin | 20.16% | -33.67% |
| Net margin | 15.15% | -41.45% |
| 52-week high | $111.86 | $35.58 |
| 52-week low | $54.94 | $8.06 |
| Distance from 52-week high | -8.73% | -76.62% |
| Analyst consensus | hold | hold |
| Avg. price target upside | +3.81% | +80.29% |
| Average volume | 1.02M | 2.04M |
| Shares outstanding | 65.40M | 68.61M |
| Employees | 1,193 | 6,500 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Lantheus is about 11.7 times larger than QuidelOrtho by market value ($6.68B vs $570.86M).
- LNTH has outperformed QDEL by 148.7 percentage points over the past year.
- Lantheus is more profitable, keeping 15.2 cents of every revenue dollar as net income versus -41.5 cents for QuidelOrtho.
About Lantheus
LNTH stock →Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 1,193 employees
About QuidelOrtho
QDEL stock →QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 6,500 employees
LNTH vs QDEL FAQ
Which is bigger, Lantheus or QuidelOrtho?
Lantheus (LNTH) is larger, with a market capitalization of $6.68B compared with $570.86M for QuidelOrtho (QDEL).
Which stock has performed better over the past year, LNTH or QDEL?
LNTH returned +82.91% over the past 12 months, compared with -65.83% for QDEL (price return, excluding dividends). Past performance does not predict future results.
Are Lantheus and QuidelOrtho in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.